First patient dosed in CatalYm’s Phase IIb visugromab trial

​CatalYm has dosed the first patient in its Phase IIb GDFATHER-HCC-01 clinical trial, assessing visugromab along with chemoimmunotherapy as a second-line treatment for patients with unresectable or metastatic HCC.

The post First patient dosed in CatalYm’s Phase IIb visugromab trial appeared first on Hospital Management.

 

Back to the Featured Stories

Featured Stories

J&J advances PFA portfolio with Varipulse Pro launch in Europe
Halozyme and Vertex sign deal for Hypercon technology
Rethinking the microbiology workflow with smarter tools for faster answers and less waste
The hidden bottleneck in digital healthcare: Why hospital wireless networks are under pressure in 2026
Stereotaxis launches Synchrony system for cath labs

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.

Contact Us